Roche’s Molecular Dx Sales Drop 3 Percent In Q3 As It Awaits FDA Clearance of Tests | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Roche reported this week that total revenue for its Molecular Diagnostics segment declined 3 percent in the third quarter, compared with the same period one year ago and matching a decline in the second quarter, but overall revenue for its entire Diagnostics business rose 4 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.